15-Year progression to liver cancer in the lack of treatment for lysosomal acid lipase deficiency: A case report

Abstract

Rationale: Lysosomal acid lipase deficiency (LAL-D) is a poorly diagnosed genetic disorder characterized by the accumulation of cholesteryl esters and triglycerides in many tissues, leading to dyslipidemia and cardiovascular complications. In the liver, deposits are found within hepatocytes and Kupffer cells, generating microvesicular steatosis, progressive fibrosis, and cirrhosis. Sebelipase alfa is the target therapy which can improve laboratory changes and reduce the progression of liver damage, but this is not yet widely available.Patient Concerns: We are reporting a 15-year follow-up of a Brazilian man who was diagnosed with cirrhosis at age 43 and with LAL-D at age 53, but he has never been treated with sebelipase alfa for economic reasons. During the coronavirus disease 2019 (COVID-19) pandemic, he lost follow-up and missed three 6-month ultrasound exams for liver cancer screening.Diagnosis: At age 58, a remarkable deterioration in liver function was observed and he was diagnosed with hepatocellular carcinoma (HCC) outside the Milan Criteria (two nodules measuring 48mm and 25mm). Three other individuals with LAL-D and progression to liver cancer have been reported so far and none of them underwent enzyme replacement therapy: an 11-year-old girl with HCC, a 51-year-old male with cholangiocarcinoma, and a 21-year-old male with hepatocellular-cholangiocarcinoma. The latter had the same mutation in the gene LIPA as our patient, but a relationship between this variant and malignancies has not yet been established. Lessons:We emphasize how important is to treat LAL-D patients after diagnosis in order to avoid worsening liver function and progression to neoplasms. Untreated individuals should be considered at a higher risk but the most appropriate liver cancer screening program for this subgroup is still unknown.

LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer

“…14 15 In humans, it has been reported that heterozygote carriers of LAL mutations altered subsets of human MDSCs, 16 and mutations in the LAL gene were linked to carcinogenesis. 17 Patients (ages ranging from 11 to 58 years) with LAL-D without enzyme replacement therapy of Sebelipase alfa (or Kanuma, commercial name for recombinant human LAL) developed hepatocellular carcinoma, cholangiocarcinoma, and hepatocellular cholangiocarcinoma, 18 suggesting that LAL serves as an attractive cancer therapy target. 19 Our recent study further supported the idea that human cancer xenotransplants were able to grow in Lal -/mice.…”